Unknown

Dataset Information

0

Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.


ABSTRACT: BACKGROUND:Eribulin mesylate is a tubulin inhibitor with activity superior to paclitaxel in NIH:OVCAR-3 human epithelial ovarian cancer xenograft models. In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum-sensitive recurrent ovarian cancer. METHODS:Patients with recurrent, measurable epithelial ovarian cancer who had received ?2 prior cytotoxic regimens and who had adequate organ function were enrolled into 2 separate cohorts: 1) platinum-resistant patients (who had a progression-free interval <6 months after their last platinum-based therapy) and 2) platinum-sensitive patients (who had a progression-free interval ?6 months after their last platinum-based therapy). Eribulin 1.4 mg/m(2) was administered over 15 minutes intravenously on days 1 and 8 every 21 days. Efficacy was determined by objective response on computed tomography studies. RESULTS:In the platinum-resistant cohort, 37 patients enrolled, and 36 patients were evaluable for response and toxicity. Two patients achieved a partial response (5.5%), and 16 patients (44%) had stable disease as their best response. The median progression-free survival was 1.8 months (95% confidence interval, 1.4-2.8 months). In the platinum-sensitive cohort, 37 patients enrolled, and all were evaluable for response. Seven patients achieved a partial response (19%). The median progression-free survival was 4.1 months (95% confidence interval, 2.8-5.8 months). The major toxicity was grade 3 or 4 neutropenia (42% of platinum-resistant patients; 54% of platinum-sensitive patients). CONCLUSIONS:Eribulin produced an objective response in 5.5% of women with platinum-resistant, recurrent ovarian cancer and in 19% of women with platinum-sensitive disease. The median progression-free survival was 1.8 months in the platinum-resistant group and 4.1 months in the platinum-sensitive group.

SUBMITTER: Hensley ML 

PROVIDER: S-EPMC3245795 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.

Hensley Martee L ML   Kravetz Sara S   Jia Xiaoyu X   Iasonos Alexia A   Tew William W   Pereira Lauren L   Sabbatini Paul P   Whalen Christin C   Aghajanian Carol A CA   Zarwan Corinne C   Berlin Suzanne S  

Cancer 20110920 9


<h4>Background</h4>Eribulin mesylate is a tubulin inhibitor with activity superior to paclitaxel in NIH:OVCAR-3 human epithelial ovarian cancer xenograft models. In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum-sensitive recurrent ovarian cancer.<h4>Methods</h4>Patients with recurrent, measurable epithelial ovarian cancer who had received ≤2 prior cytotoxic regimens and who had adequate organ function were enrolled into 2 separate cohorts: 1) platin  ...[more]

Similar Datasets

| S-EPMC3288403 | biostudies-literature
| S-EPMC4223061 | biostudies-literature
| S-EPMC3130535 | biostudies-literature
| S-EPMC6019176 | biostudies-literature
| S-EPMC3432792 | biostudies-literature
2018-02-22 | GSE98230 | GEO
2024-10-17 | PXD051500 | Pride
| S-EPMC2759418 | biostudies-literature
2020-02-11 | E-MTAB-7083 | biostudies-arrayexpress
2020-02-11 | E-MTAB-7084 | biostudies-arrayexpress